N6', N6''', and O4' Modifications to Neomycin Affect Ribosomal Selectivity Without Compromising Antibacterial Activity

Overview

Journal ACS Infect Dis

Specialties Infectious Diseases
Microbiology
Pharmacology

Date 2017 Mar 28

PMID 28343384

Citations 9

Authors

Girish C Sati

Dimitri Shcherbakov

Sven N Hobbie

Andrea Vasella

Erik C Bottger

David Crich

Affiliations

Soon will be listed here.

Abstract

The synthesis of a series of neomycin derivatives carrying the 2-hydroxyethyl substituent on N6' and/or N6‴ both alone and in combination with a 4'-O-ethyl group is described. By means of cell-free translation assays with wild-type bacterial ribosomes and their hybrids with eukaryotic decoding A sites, we investigate how individual substituents and their combinations affect activity and selectivity at the target level. In principle, and as shown by cell-free translation assays, modifications of the N6' and N6‴ positions allow enhancement of target selectivity without compromising antibacterial activity. As with the 6'OH aminoglycoside paromomycin, the 4'-O-ethyl modification affects the ribosomal activity, selectivity, and antibacterial profile of neomycin and its 6'-N-(2-hydroxyethyl) derivatives. The modified aminoglycosides show good antibacterial activity against model Gram-positive and Gram-negative microbes including the ESKAPE pathogens Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii.

Citing Articles

Phenotypic Differentiation Within the ' Aminoglycoside Resistance Gene Family Suggests a Novel Subtype IV of Contemporary Clinical Relevance.

Plattner M, Catelani M, Gmur S, Hartmann M, Kilic F, Haldimann K Antibiotics (Basel). 2025; 13(12.

PMID: 39766586 PMC: 11672645. DOI: 10.3390/antibiotics13121196.

Facile and selective -alkylation of gentamicin antibiotics chemoenzymatic synthesis.

Stojanovski G, Hailes H, Ward J Green Chem. 2022; 24(24):9542-9551.

PMID: 36544494 PMC: 9744104. DOI: 10.1039/d2gc03600b.

Synthesis and Antibacterial Activity of Propylamycin Derivatives Functionalized at the 5''- and Other Positions with a View to Overcoming Resistance Due to Aminoglycoside Modifying Enzymes.

Lubriks D, Zogota R, Sarpe V, Matsushita T, Sati G, Haldimann K ACS Infect Dis. 2021; 7(8):2413-2424.

PMID: 34114793 PMC: 8364506. DOI: 10.1021/acsinfecdis.1c00158.

Dissociating antibacterial from ototoxic effects of gentamicin C-subtypes.

OSullivan M, Song Y, Greenhouse R, Lin R, Perez A, Atkinson P Proc Natl Acad Sci U S A. 2020; 117(51):32423-32432.

PMID: 33288712 PMC: 7768767. DOI: 10.1073/pnas.2013065117.

Structure of the bacterial ribosome at 2 Å resolution.

Watson Z, Ward F, Meheust R, Ad O, Schepartz A, Banfield J Elife. 2020; 9.

PMID: 32924932 PMC: 7550191. DOI: 10.7554/eLife.60482.

References

Garneau-Tsodikova S, Labby K . Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives. Medchemcomm. 2016; 7(1):11-27. PMC: 4752126. DOI: 10.1039/C5MD00344J. View

Toda S, Nakagawa S, Naito T, Kawaguchi H . Aminoglycoside antibiotics. XV Chemical conversion of neomycin B to paromomycin I, 6"'-deamino-6"'-hydroxyneomycin B and 6"'-deamino-6"'-hydroxy-paromomycin I. J Antibiot (Tokyo). 1983; 36(1):87-91. DOI: 10.7164/antibiotics.36.87. View

Davies D, Mallams A, COUNELIS M, Loebenberg D, Moss Jr E, Waitz J . Semisynthetic aminoglycoside antibacterials. 6. Synthesis of sisomicin, Antibiotic G-52, and novel 6'-substituted analogues of sisomicin from aminoglycoside 66-40C. J Med Chem. 1978; 21(2):189-93. DOI: 10.1021/jm00200a009. View

Drusano G, Ambrose P, Bhavnani S, Bertino J, Nafziger A, Louie A . Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007; 45(6):753-60. DOI: 10.1086/520991. View

Shalev M, Rozenberg H, Smolkin B, Nasereddin A, Kopelyanskiy D, Belakhov V . Structural basis for selective targeting of leishmanial ribosomes: aminoglycoside derivatives as promising therapeutics. Nucleic Acids Res. 2015; 43(17):8601-13. PMC: 4787808. DOI: 10.1093/nar/gkv821. View

Maianti J, Kanazawa H, Dozzo P, Matias R, Feeney L, Armstrong E . Toxicity modulation, resistance enzyme evasion, and A-site X-ray structure of broad-spectrum antibacterial neomycin analogs. ACS Chem Biol. 2014; 9(9):2067-73. DOI: 10.1021/cb5003416. View

Aggen J, Armstrong E, Goldblum A, Dozzo P, Linsell M, Gliedt M . Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 2010; 54(11):4636-42. PMC: 2976124. DOI: 10.1128/AAC.00572-10. View

Salian S, Matt T, Akbergenov R, Harish S, Meyer M, Duscha S . Structure-activity relationships among the kanamycin aminoglycosides: role of ring I hydroxyl and amino groups. Antimicrob Agents Chemother. 2012; 56(12):6104-8. PMC: 3497201. DOI: 10.1128/AAC.01326-12. View

Pfister P, Hobbie S, Brull C, Corti N, Vasella A, Westhof E . Mutagenesis of 16S rRNA C1409-G1491 base-pair differentiates between 6'OH and 6'NH3+ aminoglycosides. J Mol Biol. 2005; 346(2):467-75. DOI: 10.1016/j.jmb.2004.11.073. View

10.

Green K, Chen W, Houghton J, Fridman M, Garneau-Tsodikova S . Exploring the substrate promiscuity of drug-modifying enzymes for the chemoenzymatic generation of N-acylated aminoglycosides. Chembiochem. 2009; 11(1):119-26. DOI: 10.1002/cbic.200900584. View

11.

Vicens Q, Westhof E . Molecular recognition of aminoglycoside antibiotics by ribosomal RNA and resistance enzymes: an analysis of x-ray crystal structures. Biopolymers. 2003; 70(1):42-57. DOI: 10.1002/bip.10414. View

12.

Benveniste R, Davies J . Enzymatic acetylation of aminoglycoside antibiotics by Escherichia coli carrying an R factor. Biochemistry. 1971; 10(10):1787-96. DOI: 10.1021/bi00786a009. View

13.

Potter G, Jayson G, Miller G, Gardiner J . An Updated Synthesis of the Diazo-Transfer Reagent Imidazole-1-sulfonyl Azide Hydrogen Sulfate. J Org Chem. 2016; 81(8):3443-6. DOI: 10.1021/acs.joc.6b00177. View

14.

Wasserman M, Pulk A, Zhou Z, Altman R, Zinder J, Green K . Chemically related 4,5-linked aminoglycoside antibiotics drive subunit rotation in opposite directions. Nat Commun. 2015; 6:7896. PMC: 4522699. DOI: 10.1038/ncomms8896. View

15.

Bassenden A, Rodionov D, Shi K, Berghuis A . Structural Analysis of the Tobramycin and Gentamicin Clinical Resistome Reveals Limitations for Next-generation Aminoglycoside Design. ACS Chem Biol. 2016; 11(5):1339-46. DOI: 10.1021/acschembio.5b01070. View

16.

Matt T, Ng C, Lang K, Sha S, Akbergenov R, Shcherbakov D . Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci U S A. 2012; 109(27):10984-9. PMC: 3390888. DOI: 10.1073/pnas.1204073109. View

17.

Meyer M, Freihofer P, Scherman M, Teague J, Lenaerts A, Bottger E . In vivo efficacy of apramycin in murine infection models. Antimicrob Agents Chemother. 2014; 58(11):6938-41. PMC: 4249428. DOI: 10.1128/AAC.03239-14. View

18.

Zhang J, Keller K, Takemoto J, Bensaci M, Litke A, Czyryca P . Synthesis and combinational antibacterial study of 5''-modified neomycin. J Antibiot (Tokyo). 2009; 62(10):539-44. PMC: 2783947. DOI: 10.1038/ja.2009.66. View

19.

Cassinelli G, JULITA P, ARCAMONE F . Semisynthetic aminoglycoside antibiotics. II. Synthesis of analogues of paromomycin modified in the glucosamine moiety. J Antibiot (Tokyo). 1978; 31(4):382-4. DOI: 10.7164/antibiotics.31.382. View

20.

Vakulenko S, Mobashery S . Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003; 16(3):430-50. PMC: 164221. DOI: 10.1128/CMR.16.3.430-450.2003. View